Anzeige
Mehr »
Montag, 30.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QJRW | ISIN: SE0015244520 | Ticker-Symbol: BIX0
Frankfurt
27.06.25 | 08:02
3,050 Euro
-5,43 % -0,175
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BIOINVENT INTERNATIONAL AB Chart 1 Jahr
5-Tage-Chart
BIOINVENT INTERNATIONAL AB 5-Tage-Chart
RealtimeGeldBriefZeit
3,1153,21029.06.

Aktuelle News zur BIOINVENT Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
12.06.BioInvent International: BioInvent Presents Promising Phase 2a Monotherapy Data for BI-1808 in CTCL at EHA 2025252Data from the ongoing Phase 2a study shows a 100% disease control rate with 45% of patients with advanced cutaneous T-cell lymphoma achieving an objective response:One complete response, three partial...
► Artikel lesen
11.06.BioInvent International: BioInvent Announces Promising Phase 1 Data of BI-1206 in Combination with KEYTRUDA in Solid Tumors333The Phase 1 dose escalation has been completed, and results show encouraging early signs of clinical activity in solid tumors with one complete response, one long-lasting partial response, and 11 patients...
► Artikel lesen
04.06.BioInvent International: BioInvent Presents at PAGE 2025 a Poster Highlighting Model-Informed Early Clinical Development of Anti-TNFR2 Drug Candidate BI-1910257Population model successfully developed to characterize BI-1910 pharmacokinetics and pharmacodynamics across a broad range of dosesModel will support dose selection for upcoming studies; Phase 2a as...
► Artikel lesen
27.05.XOMA Royalty purchases mezagitamab royalty rights from BioInvent International for $30M1
27.05.XOMA Royalty Corporation; BioInvent: XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million2
14.05.BioInvent International: BioInvent Presents Additional CTCL Phase 2a Data for BI-1808 Monotherapy at EHA 2025419Data from the cutaneous T-cell lymphoma (CTCL) cohort demonstrate promising clinical activity that correlates with strong immune activationOne complete response (CR), three partial responses (PR), and...
► Artikel lesen
14.05.BioInvent International: BioInvent Announces Updated Phase 2a Triple Combination Arm Data of BI-1206, rituximab, and Calquence for the Treatment of Non-Hodgkin's Lymphoma358Latest preliminary data show continued promising clinical activity in NHL patients, with two complete responses (CR), three partial responses (PR), and three stable disease (SD) as best clinical response...
► Artikel lesen
BIOINVENT Aktie jetzt für 0€ handeln
05.05.BioInvent International: BioInvent to Participate in Upcoming Investor Conferences268LUND, SE / ACCESS Newswire / May 5, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory...
► Artikel lesen
05.05.BIOINVENT INTERNATIONAL AB: BioInvent secures FDA Fast Track Designation for BI-18082
29.04.BioInvent International: Resolutions at BioInvent's Annual General Meeting 2025291LUND, SWEDEN / ACCESS Newswire / April 29, 2025 / The Annual General Meeting ("AGM") of BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) resolved to re-elect the Board members Natalie...
► Artikel lesen
29.04.BioInvent International: BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Cutaneous T-cell Lymphoma 756LUND, SE / ACCESS Newswire / April 29, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class...
► Artikel lesen
29.04.BioInvent International AB: Interim Report January - March 2025304LUND, SE / ACCESS Newswire / April 29, 2025 / BioInvent International (STO:BINV)"The first quarter of 2025 was a highly productive period across clinical development, regulatory milestones, and strategic...
► Artikel lesen
09.04.BIOINVENT INTERNATIONAL AB: Takeda's milestone payment strengthens BioInvent's business model7
08.04.BioInvent International: BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3561LUND, SWEDEN / ACCESS Newswire / April 8, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class...
► Artikel lesen
04.04.BioInvent International AB Publishes Annual Report 2024329LUND, SE / ACCESS Newswire / April 4, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class...
► Artikel lesen
01.04.BioInvent International: BioInvent to Participate in Upcoming Investor Conferences330LUND, SE / ACCESS Newswire / April 1, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class...
► Artikel lesen
25.03.Notice to Annual General Meeting in BioInvent International AB327LUND, SE / ACCESS Newswire / March 25, 2025 / BioInvent International (STO:BINV) The shareholders of BioInvent International AB (publ), Reg. No 556537-7263, are hereby invited to attend the Annual General...
► Artikel lesen
21.03.BIOINVENT INTERNATIONAL AB: BioInvent's BI-1808 gains broad FDA support1
21.03.BioInvent International: BioInvent's anti-TNFR2 antibody BI-1808 showcased at the 16th Annual T-Cell Lymphoma Forum354LUND, SE / ACCESS Newswire / March 21, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class...
► Artikel lesen
20.03.BioInvent International: BioInvent Receives FDA Orphan Drug Designation for BI-1808 for the Treatment of T-cell Lymphoma831LUND, SE / ACCESS Newswire / March 20, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class...
► Artikel lesen
Weiter >>
39 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1